Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
-seq). The candidate will design and implement CRISPR/Cas9 genome-editing experiments, analyze complex datasets, and collaborate across multidisciplinary teams. Design and execute experiments involving
-
, STED), image analysis and quantification. Advanced cell culture, transfection, molecular biology, CRISPR-Cas9, cloning, cell labeling. Protein purification, liposome formulation, in vitro reconstitutions
-
blotting CRISPR/Cas9 genome editing RNAseq and proteomics analysis Organize, process, and report experimental data. Present findings in lab meetings and contribute to manuscript and report writing
-
: 1 year Appointment Start Date: Flexible Group or Departmental Website: http://www.sheltzerlab.org (link is external) How to Submit Application Materials: Email your application to Dr. Sheltzer Does
-
Carl von Ossietzky Universität Oldenburg | Oldenburg Oldenburg, Niedersachsen | Germany | 19 days ago
recombination, marker/deficiency selection, etc.) Generation of novel transgenic Drosophila lines through appropriately designed and applied mutagenesis strategies (e.g. CRISPR-Cas/UAS/Gal4/LexA, etc.) Design
-
on proteomics (DNA pulldown/mass spectrometry) or CRISPR/Cas9 perturbation coupled with singe-cell transcriptomics (Perturb-seq). Promising hits identified in these screens will be further characterized
-
reductions in the expression of RFC1 transcript, along with impaired RFC1 function and increased sensitivity to DNA damage from platin drugs. CRISPR/Cas9 excision of the AAGGG repeat and flanking AluSx3
-
tissue 3D imaging approaches, enabling study interactions of tissue resident macrophages with fibroblasts and sensory neurons. A4. Sufficient depth of CRISPR-cas9 based gene editing in primary cells
-
The Yang Lab (https://medicine.osu.edu/find-faculty/non-clinical/molecular-medicine-and-therapeutics/liping-yang ) is recruiting a highly motivated and creative Research Scientist to join our new research
-
(IDH1/2) genes and this project focusses on how these mutations re-program liver cells, in the context of biliary cancer. We are using CRISPR-edited human cells and novel transgenic models in mice